You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring

Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer

Coiled Therapeutics doses first patient with optimised AO-252 formulation

GlycoNex commences dosing in Phase I trial of GNX1021 in Japan

IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries

Datroway approved in EU for first-line metastatic triple-negative breast cancer

Karyopharm reports topline Phase 3 trial results in endometrial cancer

Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten

10x Genomics and Lausanne University Hospital to collaborate on cancer care research

AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers

Hemogenyx partners with Lithuanian cancer centre on HG-CT-1 research and clinical programme

Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184

DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026